Radioembolization of liver metastases from colorectal cancer using Yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy

Journal of Clinical Oncology

Volumn 25, Issue 9, 2007, Pages 1099-1106

  Sharma, Ricky A ^a   Van Hazel, Guy A ^a   Morgan, Bruno ^a   Berry, David P ^a   Blanshard, Keith ^a   Price, David ^a   Bower, Geoffrey ^a   Shannon, Jennifer A ^a   Gibbs, Peter ^a   Steward, William P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; MICROSPHERE; ONDANSETRON; OXALIPLATIN; RADIOISOTOPE; YTTRIUM 90; ANTINEOPLASTIC AGENT; FOLFOX PROTOCOL; PLATINUM COMPLEX; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITAMIN B COMPLEX; YTTRIUM;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ARTIFICIAL EMBOLISM; ASTHENIA; BRACHYTHERAPY; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG POTENTIATION; FEMALE; FEVER; HUMAN; HYPOKALEMIA; LEUKOPENIA; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOEMBOLIZATION; SEPSIS; SIDE EFFECT; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AUSTRALIA; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; LIVER TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; EMBOLIZATION, THERAPEUTIC; FEMALE; FLUOROURACIL; GREAT BRITAIN; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MICROSPHERES; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; TIME FACTORS; TREATMENT OUTCOME; VITAMIN B COMPLEX; YTTRIUM RADIOISOTOPES;

EID: 34047208542     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.7916     Document Type: Article

References (39)

1. Welch J, Donaldson G: The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 189:496-502, 1979
2. Van de Velde C: Treatment of liver metastases of colorectal cancer. Ann Oncol 16:144-149, 2005
3. Navarra G, Ayav A, Weber J, et al: Short- and long-term results of intraoperative radiofrequency ablation of liver metastases. Int J Colorectal Dis 20:521-528, 2005
4. van Cutsem E, Nordlinger B, Adam R, et al: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212-2221, 2006
5. Berber E, Pelley R, Siperstein AE: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: A prospective study. J Clin Oncol 23:1358-1364, 2005
6. Ho S, Lau WY, Leung TWT, et al: Tumour-to-normal uptake ratio of Y-90 microspheres in hepatic cancer assessed with Tc-99(m) macroaggregated albumin. Br J Radiol 70:823-828, 1997
7. Campbell A, Bailey I, Burton M: Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 46:487498, 2001
8. Kennedy AS, Nutting C, Coldwell D, et al: Pathologic response and microdosimetry of 90Y microspheres in man: Review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60:1552-1563, 2004
9. Poon M, O'Connell M, Moertel C, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal cancer. J Clin Oncol 7:1407-1418, 1989
10. Raymond E, Faivre S, Chaney S, et al: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227-235, 2002
11. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
12. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
13. Goldberg R, Sargent D, Morton R, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
14. Cornelia P, Massidda B, Filippelli G, et al: Oxaliplatin plus high-dose folinic acid and 5-fluorouracil I.V. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil I.V. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 16:878-886, 2005
15. Blackstock A, Hess S, Chaney S, et al: Oxaliplatin: In vitro evidence of its radiation sensitizing activity - preclinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 45:253-254, 1999
16. Kjellstrom J, Kjellen E, Johnsson A: In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol 44:687-693, 2005
17. Khushalani NI, Leichman CG, Proulx G, et al: Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer J Clin Oncol 20: 2844-2850, 2002
18. Freyer G, Bossard N, Romestaing P, et al: Addition of oxaliplatin to continuous fluorouracil, I-folinic acid, and concomitant radiotherapy in rectal cancer: The Lyon R 97-03 phase I trial. J Clin Oncol 19:2433-2438, 2001
19. Aschele C, Friso M, Pucciarelli S, et al: A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 16:1140-1146, 2005
20. van Hazel G, Blackwell A, Anderson J, et al: Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78-85, 2004
21. Leung T, Lau W, Ho S, et al: Radiation pneumonitis after selective internal radiation treatment with intraarterial yttrium-90 microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33:919-924, 1995
22. Lau WY, Leung TWT, Ho S, et al: Diagnostic pharmaco-scintigraphy with hepatic intraarterial Tc-99m macroaggregated albumin in the determination of tumor to nontumor uptake ratio in hepatocellular carcinoma. Br J Radiol 67:136-139, 1994
23. Van Hoe L, Van Cutsem E, Vergote I, et al: Size quantification of liver metastases in patients undergoing cancer treatment: Reproducibility of one-, two-, and three-dimensional measurements determined with spiral CT. Radiology 202:671-675, 1997
24. Therasse P, Arbuck S, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
25. Terminology Committee of the International Hepato-Pancreato-Biliary Association: Brisbane 2000 terminology of liver anatomy and resections. J Hepatobiliary Pancreat Surg 2:333-339, 2000
26. National Cancer Institute: Common Terminology Criteria. http://ctep.cancer.gov/reporting/ctc.html
27. Shepherd FA, Rotstein LE, Le Houle S, et al: A phase I dose escalation trial of Y-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 70:2250-2254, 1992
28. Salem R, Lewandowski RJ, Atassi B, et al: Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627-1639, 2005
29. Carr B: Hepatic arterial 90Yttrium glass microspheres (TheraSphere) for unresectable hepatocellular carcinoma: Interim safety and survival data on 65 patients. Liver Transpl 10:S107-S110, 2004
30. Nag S, Kennedy A, Salem R, et al: Consensus Panel Meeting of The Radioembolization Brachytherapy Oncology Consortium (REBOC). University of Ohio, Columbus, ON, April 6-8, 2006
31. Geschwind JFH, Salem R, Carr BI, et al: Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127:S194-S205, 2004 (suppl 1)
32. Gray BN, Anderson JE, Burton MA, et al: Regression of liver metastases following treatment with Y-90 microspheres. Austr New Zealand J Surg 62:105-110, 1992
33. Gray B, Van Hazel G, Hope M, et al: Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711-1720, 2001
34. Lim L, Gibbs P, Yip D, et al: Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Int Med J 35:222-227, 2005
35. Stubbs RS, Cannan RJ, Mitchell AW: Selective internal radiation therapy with (90)yttrium microspheres for extensive colorectal liver metastases. J Gastrointestinal Surg 5:294-302, 2001
36. Oldendorf WH, Burroughs JT, Cassen B, et al: Beta radiation of circulating blood by an implanted shielded Y90 source, preliminary report of technique. J Nuc Med 5:883-886, 1964
37. Moroz P, Anderson JE, van Hazel G, et al: Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol 78:248-252, 2001
38. Rubbia-Brandt L, Audard V, Sartoretti P, et al: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460-466, 2004
39. Lau WY, Ho SKW, Yu SCH, et al: Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 240:299-305, 2004